New research published this week in Clinical Epigenetics, has identified two new genes linked to the development of age-related macular degeneration (AMD). Led by Dr. Louise Porter at the University of Liverpool, the team identified genes that may become new targets for treatments. 44 human donor eyes were profiled for levels of DNA methylation (a [Read More]
Author: Dan Roberts
NIH researchers prevent blindness in animal models of dry AMD
Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]
Consumed
I understand being consumed by low vision. It is hard to see the light at the end of the tunnel when there doesn’t seem to be any light. So now what? I find that, the times I focus on it, I become more scared and more consumed by what I can’t do anymore and what [Read More]
KSI-301 Joins List of Proposed Longer Lasting Anti-VEGF Drugs
Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]
Self-Monitoring For Neovascularization Can Save Vision
Neovascularization is the term applied to growth of errant blood vessels into the retina. This can occur whenever the retina is compromised by diseases such as age-related macular degeneration, myopic degeneration, or diabetic macular edema. Neovascularization is initially identified during dilated eye examinations, the scheduling of which depends upon the patient’s initiative in acquiring and [Read More]